UroGen Pharma Ltd.

URGN

NASDAQ

Healthcare

Biotechnology

Princeton, NJ, US234 employeesurogen.com

$18.84

-0.10(-0.53%)

Mkt Cap $917M

$3.93

$29.42

52-Week Range

At A Glance

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

Revenue is primarily driven by Jelmyto (92.1%) and Zusduri (7.9%).

Most recently: , including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, (2026-03-02).

$917M

Market Cap

$109M

Revenue

-$152M

Net Income

Employees234

Fundamentals

How The Business Makes Money

Revenue by Segment

Jelmyto92.1%($184M)

Zusduri7.9%($16M)

Activity

What Changed Recently

Financial Results

Mar 1, 2026

, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,

Material Agreement

Mar 1, 2026

Entry into a Material Definitive Agreement. On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” a

Peer Companies

Company	Price	Change	Market Cap	P/E
TNGXTango Therapeutics, Inc.	$21.66	+2.07%	$2.5B	-21.7
KODKodiak Sciences Inc.	$40.55	-5.28%	$2.1B	-5.4
ANABAnaptysBio, Inc.	$57.98	+2.20%	$1.7B	-131.7
MNMDMind Medicine (MindMed) I...	$20.65	+0.24%	$1.6B	-8.8
OCSOculis Holding AG	$26.48	-2.03%	$1.5B	-11.0
NRIXNurix Therapeutics, Inc.	$15.51	+0.16%	$1.3B	-5.3
XNCRXencor, Inc.	$12.79	+2.11%	$938M	-9.7
PHATPhathom Pharmaceuticals, ...	$11.35	+1.89%	$894M	-3.5

Analyst View

Company Profile

CIK0001668243

ISINIL0011407140

CUSIPM96088105

Phone646 768 9780

Address400 Alexander Park, Princeton, NJ, 08540, US

SEC EDGAR